At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles focused on the use of antibody drug conjugates for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects. Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center. ...
The Uromigos Live & Unplugged: Bladder Cancer
Advertisement
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
In this third segment, the panelists discuss bladder-sparing approaches.
The second part of this four-part segment includes conversation about ctDNA in bladder cancer.
The first part of four segments from the panel session on peri-operative therapy in bladder cancer.
Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024.
Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024.
View the live recording of the "Will New Antibody Drug Conjugates Cure Bladder Cancer?" session from Uromigos Live 2024.
Peri-Operative Therapy in Urothelial Carcinoma: Live Session From The Uromigos Live & Unplugged 2024
Featuring Tom Powles, MD; Petros Grivas, MD; Shilpa Gupta, MD; Kala Sridhar, MD; and Andrea Apolo, MD. 
The panel discussed the latest updates in NMIBC, including relevant data pertaining to pembro, atezo, and more.
The panel discussed the latest data and updates in frontline bladder cancer during a livestreamed session.
Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma.
Drs. Powles, Tawagi, and Berg highlight attempts to define 2L SOC options, as well IO rechallenging in bladder cancer.
Dr. Pedro Barata discusses his thoughts on the use of cisplatin in patients with bladder cancer, as well as CheckMate 901.
Dr. Vadim Koshkin gives his thoughts on the CheckMate 901 study and its data that were presented at the conference.
Dr. Petros Grivas discusses new bladder cancer data, including the TAR-200 delivery system and the SunRISe trials.
Patient advocate Mary Beth Ballard discusses how new research and data gives hope to patients with bladder cancer.
Dr. Gautam Jayram discusses his biggest takeaways from the event, including panels on non-muscle invasive bladder cancer.
Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC.
Dr. Karine Tawagi discusses her proposed trial on a phase 2 multi-arm parallel trial for metastatic UC.
Dr. O'Donnell shares his impression of the data at ESMO and offers a positive outlook on the future of UC.
Dr. Stephanie Berg describes her presentation given on second-line treatment for mUC during the Rising Stars panel.
Brian Rini, MD, asks Sam Chang, MD, and Sia Daneshmand, MD, about their takeaways from the session on NMIBC.
Dr. Terence Friedlander provides his take on CheckMate 901 and the enfortumab vedotin/pembrolizumab combination.
Tom is joined by Drs. Chang, Daneshmand, and Grivas to discuss new therapies in NMIBC and BCG-refractory NMIBC.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.